EGEllen M. Ginzler

Ellen M. Ginzler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ellen M. Ginzler has a total of 165 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dialogue: commentary on ‘Engaging African-ancestry participants in systemic lupus erythematosus clinic trials’

    by Ellen M Ginzler

    In the review entitled Engaging African-Ancestry Participants in Systemic Lupus Erythematosus Clinic Trials , Anjorin and Lipsky1 sought to (1) summarise the extensive body of literature demonstrating differences in genetics and health impact in African American (AA) patients with SLE compared with European American (EA) counterparts, and (2) describe challenges in recruiting AA for clinical trials. Several facts in their comprehensive review are indisputable: systemic lupus disproportionately affects individuals of African ancestry (and probably other racial/ethnic groups such as Hispanics and Asians) compared with Caucasians; the clinical and immunological manifestations, damage accrual and morbidity of SLE tend to be more severe in those of African ancestry; and such individuals are often more socioeconomically disadvantaged, which may lead to problems with access to medical care, at least in …


  • Open Access

    Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study

    by Isabel Ferreira, Sara Croca, Maria Gabriella Raimondo, Manjit Matharu, Sarah Miller, Ian Giles, David Isenberg, Yiannis Ioannou, John G. Hanly, Murray B. Urowitz, et al.

    In patients with systemic lupus erythematosus (SLE) there is no serological test that will reliably distinguish neuropsychiatric (NP) events due to active SLE from those due to other causes. Previously we showed that serum levels of nitrated nucleosomes (NN) were elevated in a small number of patients with NPSLE. Here we measured serum NN in samples from a larger population of patients with SLE and NP events to see whether elevated serum NN could be a marker for NPSLE. We obtained serum samples from patients in the Systemic Lupus International Collaborative Clinics (SLICC) inception cohort. This included 216 patients with NP events and two matched controls with SLE but no NP events for each of these patients. For the NP patients we tested samples taken before, during and after the NP event. Twenty-six patients had events attributed to SLE according to the most stringent SLICC attribution rule. In these patients there was no association between onset of event and elevated serum NN. In 190 patients in whom events were not attributed to SLE by the SLICC rules, median serum NN was elevated at the onset of event (P = 0.006). The predominant clinical features in this group of 190 patients were headache, mood disorders and anxiety. Serum NN levels rise at the time of an NP event in a proportion of patients with SLE. Further studies are needed to determine the value of serum NN as a biomarker for NPSLE.


  • Open Access

    Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials

    by William Stohl, Joan T. Merrill, R. John Looney, Jill Buyon, Daniel J. Wallace, Michael H. Weisman, Ellen M. Ginzler, Blaire Cooke, Donna Holloway, Arunan Kaliyaperumal, et al.

    Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to both cell membrane-expressed and soluble BAFF. The goal of these first-in-human studies was to characterize the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of blisibimod in subjects with systemic lupus erythematosus (SLE). SLE subjects with mild disease that was stable/inactive at baseline received either a single dose of blisibimod (0.1, 0.3, 1, or 3 mg/kg subcutaneous [SC] or 1, 3, or 6 mg/kg intravenous [IV]) or placebo (phase 1a; N = 54), or four weekly doses of blisibimod (0.3, 1, or 3 mg/kg SC or 6 mg/kg IV) or placebo (phase 1b; N = 63). Safety and tolerability measures were collected, and B cell subset measurements and pharmacokinetic analyses were performed. All subjects (93 % female; mean age 43.7 years) carried the diagnosis of SLE for ≥ 1 year. Single- and multiple-dose treatment with blisibimod produced a decrease in the number of naïve B cells (24–76 %) and a transient relative increase in the memory B cell compartment, with the greatest effect on IgD-CD27+; there were no notable changes in T cells or natural killer cells. With time, memory B cells reverted to baseline, leading to a calculated 30 % reduction in total B cells by approximately 160 days after the first dose. In both the single- and multiple-dosing SC cohorts, the pharmacokinetic profile indicated slow absorption, dose-proportional exposure from 0.3 through 3.0 mg/kg SC and 1 through 6 mg/kg IV, linear pharmacokinetics across the dose range of 1.0–6.0 mg/kg, and accumulation ratios ranging from 2.21 to 2.76. The relative increase in memory B cells was not associated with safety signals, and the incidence of adverse events, anti-blisibimod antibodies, and clinical laboratory abnormalities were comparable between blisibimod- and placebo-treated subjects. Blisibimod changed the constituency of the B cell pool and single and multiple doses of blisibimod exhibited approximate dose-proportional pharmacokinetics across the dose range 1.0–6.0 mg/kg. The safety and tolerability profile of blisibimod in SLE was comparable with that of placebo. These findings support further studies of blisibimod in SLE and other B cell-mediated diseases. Clinicaltrials.gov NCT02443506 . Registered 11 May 2015. NCT02411136 Registered 7 April 2015.


  • Open Access

    Significance of cerebrovascular reactivity in patients with systemic lupus erythematosus

    by Jason Lazar, Louis Salciciolli, Elina Malamed, Ellen M Ginzler

  • Open Access

    Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients

    by Sasha Bernatsky, Rosalind Ramsey-Goldman, Jean-François Boivin, Lawrence Joseph, Michelle A Petri, Asad Zoma, Susan Manzi, Murray B Urowitz, Dafna D Gladman, Paul R Fortin, et al.

  • Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus

    by Ellen M. Ginzler, Daniel J. Wallace, Joan T. Merrill, Richard A. Furie, William Stohl, W. Winn Chatham, Arthur Weinstein, James D. McKay, W. Joseph McCune, Z. John Zhong, et al.

    Objective.: To evaluate the efficacy/safety of belimumab plus standard therapy in patients (n = 449) with active systemic lupus erythematosus (SLE) treated up to 7 years (n = 177 currently ongoing).Methods.: Patients (n = 345) who completed a double-blind, placebo-controlled, 52-week study of belimumab 1, 4, or 10 mg/kg and 24-week extension of belimumab (placebo switched to 10 mg/kg; belimumab same dose or switched to 10 mg/kg) could receive belimumab 10 mg/kg in an open-label continuation study (n = 296). Disease activity was analyzed in patients with active SLE at baseline of the initial study. Biomarker and SLE medication changes were evaluated, and adverse events (AE) were monitored throughout the study.Results.: Total belimumab exposure over 7 years (double-blind and open-label periods): 1746 patient-years. SLE Responder Index (SRI) response rates at Week 52 in autoantibody-positive patients: placebo, 29%; belimumab, 46% (p < 0.05). In the continuation study, 57% of auto-antibody-positive patients had an SRI response by Year 2 and 65% by Year 7; severe flares occurred in 19% with placebo and 17% with belimumab during the first year, with the annual rate declining to 2%–9% during years 2–7. Anti-dsDNA autoantibodies in patients positive for them at baseline had a progressive decline of 40%–60% from baseline over 2–7 years with belimumab. Corticosteroid use decreased over time with ≥ 50–55% reduction in median dose during years 5–7. Serious and overall annual AE rates, including infections, were generally stable or decreased during 7-year treatment.Conclusion.: Disease control and safety profile were maintained in patients with active SLE taking belimumab plus standard therapy for up to 7 years. [ClinicalTrials.gov numbers: NCT00071487 and NCT00583362]


  • Management of lupus nephritis—new guidelines revealed

    by Ellen Ginzler

    The past decade has seen exciting progress in the management of lupus nephritis, a manifestation of systemic lupus erythematosus that accounts for its major morbidity and mortality. The American College of Rheumatology has issued new guidelines for screening and treatment of lupus nephritis, based on expert recommendations.